Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience

Hicham Skali, Hans-Henrik Parving, Patrick S Parfrey, Emmanuel A Burdmann, Eldrin F Lewis, Peter Ivanovich, Sai Ram Keithi-Reddy, Janet B McGill, John J V McMurray, Ajay K Singh, Scott D Solomon, Hajime Uno, Marc A Pfeffer, TREAT Investigators

    84 Citationer (Scopus)

    Abstract

    More strokes were observed in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT) among patients assigned to darbepoetin alfa. We sought to identify baseline characteristics and postrandomization factors that might explain this association.
    OriginalsprogEngelsk
    TidsskriftCirculation (Baltimore)
    Vol/bind124
    Udgave nummer25
    Sider (fra-til)2903-8
    Antal sider6
    ISSN0009-7322
    DOI
    StatusUdgivet - 2011

    Fingeraftryk

    Dyk ned i forskningsemnerne om 'Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience'. Sammen danner de et unikt fingeraftryk.

    Citationsformater